Review highlights targeted nanoparticle drug carriers in cardiovascular disease, indicating potential to reduce dosages and minimize systemic adverse effects.
Despite its prevalence, cardiovascular disease lacks a universally effective pharmacotherapy strategy preventing against its progression. One possible strategy involves the use of nanoparticles as drug carriers to increase the effectiveness of existing preparations and thus reduce the dose. This can minimize the side effects and target the therapy in the affected areas. Currently, nanoparticles of lipid, polymeric, or even metabolic origin are being developed, and clinical trials are underway to determine the effectiveness of this type of therapy.
No takes yet. Share an insight, caveat, or question.
Dominiak et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: